Payment overview · 2025
General Payments
$307.30
17 reported records · 10 companies
Healthcare provider profile · identity verified
Tae Yu, DO
Allopathic & Osteopathic Physicians|Family Medicine · PERRY, FL · NPI 1861440141
Verified facts
What the public records show
CMS Open Payments records show Tae Yu, DO received $307.30 in general payments during 2025 across 17 reported records.
PFIZER INC. accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Mounjaro, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Symbicort by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nucynta as an associated drug or biological on 230 records involving 95 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nucynta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.63 | 21.4% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.22 | 13.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.83 | 12.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $35.92 | 11.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.63 | 10.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.40 | 7.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.11 | 6.5% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.66 | 6.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.21 | 5.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.69 | 5.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $307.30 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $65.63 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $65.63 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $40.22 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $38.83 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $35.92 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $35.92 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $20.11 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 206 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
87 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | Nucynta open payments reported associated product |
CMS Open Payments — General Payments 230 supporting records · 95 recipient NPIs · example record 1224105108 |
Nucynta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
206 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 717 | 111 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 629 | 101 |
| Atorvastatin Calcium | Atorvastatin Calcium | 574 | 162 |
| Omeprazole | Omeprazole | 479 | 131 |
| Tramadol Hcl | Tramadol Hcl | 451 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 422 | 111 |
| Furosemide | Furosemide | 375 | 75 |
| Gabapentin | Gabapentin | 306 | 81 |
| Lisinopril | Lisinopril | 306 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 298 | 93 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 287 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 271 | 90 |
| Zolpidem Tartrate | Zolpidem Tartrate | 255 | 45 |
| Metformin Hcl | Metformin Hcl | 235 | 64 |
| Clonazepam | Clonazepam | 229 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 227 | 38 |
| Losartan Potassium | Losartan Potassium | 210 | 65 |
| Simvastatin | Simvastatin | 208 | 55 |
| Eliquis | Apixaban | 206 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 198 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 196 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 179 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 177 | 48 |
| Montelukast Sodium | Montelukast Sodium | 176 | 49 |
| Ezetimibe | Ezetimibe | 167 | 45 |
| Pregabalin | Pregabalin | 151 | 31 |
| Carvedilol | Carvedilol | 148 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 129 | 46 |
| Baclofen | Baclofen | 126 | 24 |
| Temazepam | Temazepam | 121 | 14 |
| Allopurinol | Allopurinol | 120 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 42 |
| Lorazepam | Lorazepam | 118 | 23 |
| Potassium Chloride | Potassium Chloride | 118 | 31 |
| Trazodone Hcl | Trazodone Hcl | 117 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 114 | 28 |
| Meloxicam | Meloxicam | 114 | 30 |
| Famotidine | Famotidine | 113 | 30 |
| Celecoxib | Celecoxib | 109 | 35 |
| Januvia | Sitagliptin Phosphate | 105 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 103 | 26 |
| Sertraline Hcl | Sertraline Hcl | 97 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 93 | 25 |
| Ozempic | Semaglutide | 92 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 91 | 69 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 36 |
| Glimepiride | Glimepiride | 89 | 28 |
| Testosterone Cypionate | Testosterone Cypionate | 88 | 23 |
| Linzess | Linaclotide | 87 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 81 | 23 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 75 | 12 |
| Clonidine Hcl | Clonidine Hcl | 75 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 70 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 70 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 69 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 19 |
| Prednisone | Prednisone | 68 | 29 |
| Glipizide Er | Glipizide | 67 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 18 |
| Memantine Hcl | Memantine Hcl | 64 | 11 |
| Nystatin | Nystatin | 63 | 25 |
| Levofloxacin | Levofloxacin | 61 | 44 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 59 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 59 | suppressed |
| Diazepam | Diazepam | 56 | 13 |
| Metformin Hcl Er | Metformin Hcl | 56 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 33 |
| Buspirone Hcl | Buspirone Hcl | 53 | 11 |
| Azithromycin | Azithromycin | 52 | 39 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 30 |
| Jardiance | Empagliflozin | 50 | 12 |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Eszopiclone | Eszopiclone | 49 | suppressed |
| Spironolactone | Spironolactone | 49 | 14 |
| Myrbetriq | Mirabegron | 48 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 47 | 14 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 18 |
| Finasteride | Finasteride | 46 | 17 |
| Meclizine Hcl | Meclizine Hcl | 45 | 17 |
| Mirtazapine | Mirtazapine | 45 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 22 |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Ondansetron Odt | Ondansetron | 44 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | suppressed |
| Glipizide | Glipizide | 43 | suppressed |
| Ibuprofen | Ibuprofen | 42 | suppressed |
| Methadone Hcl | Methadone Hcl | 42 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 22 |
| Sucralfate | Sucralfate | 42 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 41 | suppressed |
| Fentanyl | Fentanyl | 41 | suppressed |
| Naproxen | Naproxen | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | 15 |
| Estradiol | Estradiol | 40 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 40 | suppressed |
| Nitroglycerin | Nitroglycerin | 40 | 14 |
| Latanoprost | Latanoprost | 38 | suppressed |
| Repatha Sureclick | Evolocumab | 37 | suppressed |
| Fenofibrate | Fenofibrate | 36 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Atenolol | Atenolol | 35 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 27 |
| Methylprednisolone | Methylprednisolone | 35 | 28 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | 11 |
| Scopolamine | Scopolamine | 32 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | 12 |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Methimazole | Methimazole | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 12 |
| Erythromycin | Erythromycin Base | 24 | 11 |
| Valsartan | Valsartan | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 13 |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | 12 |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Novolin R | Insulin Regular, Human | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | 11 |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Nucynta | Tapentadol Hcl | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Ivermectin | Ivermectin | 12 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | 11 |
| Nadolol | Nadolol | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $307.30 · 17 records | PFIZER INC. | Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, FARXIGA, Jornay PM, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, The Cologuard Plus Collection Kit, VERQUVO, VRAYLAR, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error